Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00894517 · ClinicalTrials.gov registry record · Phase 1

A Study Evaluating the Effect of Botulinum Toxin Type A on Semen Quality in Patients With Benign Prostatic Hyperplasia

A Phase 1 study of Benign Prostatic Hyperplasia, sponsored by Allergan.

Completed
Registry status
Phase 1
Development phase
61
Enrollment target
1
Study location

NCT00894517: Completed Phase 1 study of Benign Prostatic Hyperplasia, sponsored by Allergan.

NCT00894517 is a Phase 1 study of Benign Prostatic Hyperplasia that has completed, run by Allergan. The registered enrollment target is 61 participants, below the 550-participant average among 29 other Benign Prostatic Hyperplasia trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00894517, a Phase 1 study of Benign Prostatic Hyperplasia, has completed, sponsored by Allergan.

COMPLETED
Registry status
Phase 1
Development phase
61 participants
Enrollment target
1
Study location

Study Summary

This is a 24 week study evaluating the effects of botulinum toxin Type A on semen quality in patients with signs and symptoms of Benign Prostatic Hyperplasia (BPH).

Primary Outcome

Sperm count per ejaculate was calculated based on the average of two semen samples collected 2 to 5 days apart at Baseline and at Week 12. Ejaculatory volume and sperm concentration were used to determine the total sperm count per ejaculate. A positive percent change from Baseline indicated improvement.

Conditions Studied

Benign Prostatic Hyperplasia

Interventions

  • BIOLOGICAL Botulinum Toxin Type A
  • DRUG Placebo (saline)

Study Locations (1)

California

  • - Los Angeles

Trial Details

FieldValue
Enrollment Target 61 participants
Start Date 2009-08
Est. Completion 2012-08
Phase Phase 1
Allergan

314 total trials

What the finished NCT00894517 record still lists

NCT00894517 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 61 participants, a relatively small participant target, below the 550-participant average among 29 other Benign Prostatic Hyperplasia trials with a reported enrollment target (89% lower).

The record links to 1 condition, with Benign Prostatic Hyperplasia appearing as the primary indexed condition, and to 2 interventions - of which Botulinum Toxin Type A is the first listed.

NCT00894517 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT00894517 about?

NCT00894517 is a clinical study titled "A Study Evaluating the Effect of Botulinum Toxin Type A on Semen Quality in Patients With Benign Prostatic Hyperplasia". This is a 24 week study evaluating the effects of botulinum toxin Type A on semen quality in patients with signs and symptoms of Benign Prostatic Hyperplasia (BPH).

What is the current status of trial NCT00894517?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 61 participants. The study started on 2009-08. Estimated completion is 2012-08.

What conditions does trial NCT00894517 study?

This clinical trial studies the following conditions: Benign Prostatic Hyperplasia.

What interventions are being tested in trial NCT00894517?

The interventions under investigation include: Botulinum Toxin Type A (BIOLOGICAL), Placebo (saline) (DRUG).

Who is sponsoring clinical trial NCT00894517?

This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00894517 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Benign Prostatic Hyperplasia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00894517's enrollment target sits among peer trials

61 24th of 29 higher than 6 of 29 other Benign Prostatic Hyperplasia trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Benign Prostatic Hyperplasia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04115306 · 61 participants · Phase 1

    Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer

  • NCT05070845 · 61 participants · Phase 2

    Safety and Efficacy Study of PF-06835375 in Primary Immune Thrombocytopenia

  • NCT05187832 · 61 participants · Phase 1

    A Study of AND019 in Women With ER Positive HER2 Negative Advanced or Metastatic Breast Cancer

  • NCT05269316 · 61 participants · Phase 1

    Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT00894517, the US trial registry maintained by the National Library of Medicine. NCT00894517 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.